Express Scripts, part of Cigna’s Evernorth, is overhauling its pharmacy benefits model to lower out-of-pocket costs and boost ...

Milestone Pharmaceuticals Inc (MIST) reports a successful product launch and strategic trials, despite facing early-stage revenue hurdles and increased expenses.

If you've been relying on Express Scripts for your 90-day refills and home delivery, 2026 brings a critical shift: a new 'Copay Assurance' program that caps out-of-pocket costs, paired with stricter ...

The company initiated its next development program for etripamil, starting a Phase III AFib-RVR trial. “We have initiated our Phase III trial for atrial fibrillation with rapid ventricular rate or ...

Future commercial investments will be ROI-driven, with potential sales force expansion and increased patient activation ...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress ...

Independent pharmacies fear closure as profit margins grow slim for high-cost prescription drugs, while members of the South ...

Concerns about health care affordability, intensifying scrutiny of rebate practices, and new pricing models are creating ...

Pressures converging pharmacy include rising drug costs, supply instability, and regulatory changes impacting health systems and patient access.

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal ...

Running two drugstores is a break-even endeavor for Primary Care Pharmacy Services owner Anthony Bertola, as long as he ...